TNFRSF11A and osteoporosis: In the past two decades, it has been well demonstrated that RANKL (also known as TNFSF11) binding to its receptor RANK (also known as TNFRSF11A) drives osteoclast development and it is considered a crucial target protein for osteoporosis treatments [23].